{"id":3059,"date":"2026-05-29T00:49:12","date_gmt":"2026-05-29T07:49:12","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=3059"},"modified":"2026-05-29T02:42:24","modified_gmt":"2026-05-29T09:42:24","slug":"yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/","title":{"rendered":"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">On May 21, the NMPA website announced that Yangtze River Pharmaceutical Group (YRPG)&#8217;s Class 1 new drug\u00a0<strong>Fazamorexant Tablets\u00a0<\/strong>had been approved for marketing in China for the treatment of insomnia. This is the first domestic dual orexin receptor antagonist approved in China.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Fazamorexant (development code: YZJ-1139) is a potent antagonist of both orexin type 1 and type 2 receptors (OX1R and OX2R). It improves sleep by inhibiting orexin receptors, including accelerating sleep onset and prolonging sleep duration. Additionally, Fazamorexant has the advantages of rapid absorption and a moderate half-life, enabling fast onset of action and low next\u001eday residual effects.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This approval is based on positive results from a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial (registration numbers: NCT05525637 \/ CTR20212685). The study aimed to evaluate the efficacy and safety of Fazamorexant. The results were presented globally for the first time at the World Sleep 2025 congress (World Sleep 2025) and the Asian Society of Sleep Medicine Annual Meeting (ASSM 2025). The results showed that Fazamorexant, as a dual orexin receptor antagonist, demonstrated rapid onset of action and a favorable safety profile in adult patients with insomnia.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In terms of safety, Fazamorexant was well tolerated, with a low discontinuation rate due to adverse events (0.6%). No rebound insomnia or withdrawal symptoms were observed after treatment cessation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On May 21, the NMPA website announced that Yangtze River Pharmaceutical Group (YRPG)&#8217;s Class 1 new drug\u00a0Fazamorexant Tablets\u00a0had been approved for marketing in China for the treatment of insomnia. This is the first domestic dual orexin receptor antagonist approved in China. Fazamorexant (development code: YZJ-1139) is a potent antagonist of both orexin type 1 and [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":3090,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-3059","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market - Xpharma China<\/title>\n<meta name=\"description\" content=\"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T07:49:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T09:42:24+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/Yangtze-River-Pharmaceutical-Group.png\" \/>\n\t<meta property=\"og:image:width\" content=\"420\" \/>\n\t<meta property=\"og:image:height\" content=\"310\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market\",\"datePublished\":\"2026-05-29T07:49:12+00:00\",\"dateModified\":\"2026-05-29T09:42:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/\"},\"wordCount\":226,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Yangtze-River-Pharmaceutical-Group.png\",\"articleSection\":[\"Approved News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/\",\"name\":\"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Yangtze-River-Pharmaceutical-Group.png\",\"datePublished\":\"2026-05-29T07:49:12+00:00\",\"dateModified\":\"2026-05-29T09:42:24+00:00\",\"description\":\"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Yangtze-River-Pharmaceutical-Group.png\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Yangtze-River-Pharmaceutical-Group.png\",\"width\":420,\"height\":310},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market - Xpharma China","description":"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/","og_locale":"en_US","og_type":"article","og_title":"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market - Xpharma China","og_description":"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-05-29T07:49:12+00:00","article_modified_time":"2026-05-29T09:42:24+00:00","og_image":[{"width":420,"height":310,"url":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/Yangtze-River-Pharmaceutical-Group.png","type":"image\/png"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market","datePublished":"2026-05-29T07:49:12+00:00","dateModified":"2026-05-29T09:42:24+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/"},"wordCount":226,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/Yangtze-River-Pharmaceutical-Group.png","articleSection":["Approved News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/","url":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/","name":"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/Yangtze-River-Pharmaceutical-Group.png","datePublished":"2026-05-29T07:49:12+00:00","dateModified":"2026-05-29T09:42:24+00:00","description":"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/Yangtze-River-Pharmaceutical-Group.png","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/Yangtze-River-Pharmaceutical-Group.png","width":420,"height":310},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-fazamorexant-tablets-class-1-new-anti-insomnia-drug-approved-for-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market"}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=3059"}],"version-history":[{"count":1,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3059\/revisions"}],"predecessor-version":[{"id":3064,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3059\/revisions\/3064"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media\/3090"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=3059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=3059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=3059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}